Abstract:Sepsis is a major cause of mortality in intensive care units, which results from a severely dysregulated inflammatory response that ultimately leads to organ failure. While antibiotics can help in the early stages, effective strategies to curtail inflammation remain limited. The high mobility group (HMG) proteins are chromosomal proteins with important roles in regulating gene transcription. While HMGB1 has been shown to play a role in sepsis, the role of other family members including HMGXB4 remains unknown. We found that expression of HMGXB4 is strongly induced in response to lipopolysaccharide (LPS)-elicited inflammation in murine peritoneal macrophages. Genetic deletion of Hmgxb4 protected against LPS-induced lung injury and lethality and cecal ligation and puncture (CLP)-induced lethality in mice, and attenuated LPS-induced proinflammatory gene expression in cultured macrophages. By integrating genome-wide transcriptome profiling and a publicly available ChIP-seq dataset, we identified HMGXB4 as a transcriptional activator that regulates the expression of the proinflammatory gene, Nos2 (inducible nitric oxide synthase 2) by binding to its promoter region, leading to NOS2 induction and excessive NO production and tissue damage. Similar to Hmgxb4 ablation in mice, administration of a pharmacological inhibitor of NOS2 robustly decreased LPS-induced pulmonary vascular permeability and lethality in mice. Additionally, we identified the cell adhesion molecule, ICAM1, as a target of HMGXB4 in endothelial cells that facilitates inflammation by promoting monocyte attachment. In summary, our study reveals a critical role of HMGXB4 in exacerbating endotoxemia via transcriptional induction of Nos2 and Icam1 gene expression and thus targeting HMGXB4 may be an effective therapeutic strategy for the treatment of sepsis.

Novel Insights For High Mobility Group Box 1 Protein-Mediated Cellular Immune Response In Sepsis: A Systemic Review

Inflammatory Response and Immune Regulation of High Mobility Group Box-1 Protein in Treatment of Sepsis.

Targeting HMGB1 for the treatment of sepsis and sepsis-induced organ injury

Deficiency of the Novel High Mobility Group Protein HMGXB4 Protects Against Systemic Inflammation-Induced Endotoxemia in Mice.

The Regulatory Role of High-Mobility Group Protein 1 in Sepsis-Related Immunity

Therapeutic Potential of HMGB1-targeting Agents in Sepsis.

High mobility group protein 1: a new target in sepsis therapy

[Advances in high mobility group box-1 protein mediated multiple organ dysfunction and its potential interventional strategies].

Pathophysiological Function of HMGB1 As a Late- Acting Mediator of Inflammation

HMGB1, a potent proinflammatory cytokine in sepsis.

Recent advances in the biology of IL-1 family cytokines and their potential roles in development of sepsis.

High Mobility Group Box 1 Protein As a Potential Drug Target for Infection- and Injury-Elicited Inflammation.

Therapeutic targeting of HMGB1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes

Inhibition of Cerebral High-Mobility Group Box 1 Protein Attenuates Multiple Organ Damage and Improves T Cell-Mediated Immunity in Septic Rats

Relationship Between High Mobility Group Box- 1 Protein and Inflammation

[The Potential Role of High Mobility Group Box 1 Protein in Immune Dysfunction and Its Regulatory Mechanism after Major Trauma].

[The Extracellular Role of High Mobility Group Box-1 Protein in Regulation of Immune Response].

Relationship of high mobility group boxl and inflammation

Antagonism of Cerebral High Mobility Group Box 1 Ameliorates Dendritic Cell Dysfunction in Sepsis

High Mobility Group Protein 1 Reverses Immune System Paralysis in Late-Phase Sepsis

High-mobility Group Box 1 Mediates Persistent Splenocyte Priming in Sepsis Survivors: Evidence from a Murine Model.